ITCI Intra Cellular Therapies Inc

Intra-Cellular Therapies Inc is a biopharmaceutical company. It is engaged in discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders.

$57.09  -1.22 (-2.09%)
As of 06/30/2022 15:59:58 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/27/2013
Outstanding shares:  94,324,313
Average volume:  723,581
Market cap:   $5,209,531,807
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BHCB0P4
Valuation   (See tab for details)
PE ratio:   -18.12
PB ratio:   6.92
PS ratio:   50.59
Return on equity:   -38.29%
Net income %:   -294.72%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy